ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotaviru… Read more
Market Cap & Net Worth: ImmuCell Corporation (ICCC)
ImmuCell Corporation (NASDAQ:ICCC) has a market capitalization of $54.73 Million ($54.73 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22727 globally and #8012 in its home market, demonstrating a -6.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ImmuCell Corporation's stock price $6.05 by its total outstanding shares 9045851 (9.05 Million).
ImmuCell Corporation Market Cap History: 2015 to 2026
ImmuCell Corporation's market capitalization history from 2015 to 2026. Data shows change from $68.21 Million to $54.73 Million (-1.12% CAGR).
Index Memberships
ImmuCell Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #607 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2012 of 3165 |
Weight: ImmuCell Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ImmuCell Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ImmuCell Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.76x
ImmuCell Corporation's market cap is 1.76 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $68.21 Million | $10.23 Million | $1.21 Million | 6.67x | 56.22x |
| 2016 | $53.82 Million | $9.54 Million | $508.45K | 5.64x | 105.86x |
| 2017 | $79.51 Million | $10.43 Million | -$168.00K | 7.62x | N/A |
| 2018 | $63.74 Million | $10.99 Million | -$2.32 Million | 5.80x | N/A |
| 2019 | $46.59 Million | $13.72 Million | -$1.30 Million | 3.39x | N/A |
| 2020 | $53.82 Million | $15.34 Million | -$1.02 Million | 3.51x | N/A |
| 2021 | $72.37 Million | $19.24 Million | -$78.29K | 3.76x | N/A |
| 2022 | $55.18 Million | $18.57 Million | -$2.49 Million | 2.97x | N/A |
| 2023 | $46.04 Million | $17.47 Million | -$5.77 Million | 2.64x | N/A |
| 2024 | $46.59 Million | $26.49 Million | -$2.16 Million | 1.76x | N/A |
Competitor Companies of ICCC by Market Capitalization
Companies near ImmuCell Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to ImmuCell Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ImmuCell Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, ImmuCell Corporation's market cap moved from $68.21 Million to $ 54.73 Million, with a yearly change of -1.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $54.73 Million | -1.63% |
| 2025 | $55.63 Million | +19.42% |
| 2024 | $46.59 Million | +1.18% |
| 2023 | $46.04 Million | -16.56% |
| 2022 | $55.18 Million | -23.75% |
| 2021 | $72.37 Million | +34.46% |
| 2020 | $53.82 Million | +15.53% |
| 2019 | $46.59 Million | -26.91% |
| 2018 | $63.74 Million | -19.84% |
| 2017 | $79.51 Million | +47.73% |
| 2016 | $53.82 Million | -21.09% |
| 2015 | $68.21 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ImmuCell Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $54.73 Million USD |
| MoneyControl | $54.73 Million USD |
| MarketWatch | $54.73 Million USD |
| marketcap.company | $54.73 Million USD |
| Reuters | $54.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.